Clinical Trial Detail

NCT ID NCT03769103
Title Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors British Columbia Cancer Agency
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: adult senior

No variant requirements are available.